Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Mental Health (NIMH) is seeking research aimed at identifying optimal dosing strategies for new psychiatric medications in children and adolescents with serious mental illnesses. This initiative focuses on creating and refining central nervous system (CNS) tools and models that demonstrate how these medications affect the developing brain. Such tools may include advanced neuroimaging techniques like EEG or fMRI, digital health measures, and cognitive assessments. The research should explore the relationship between dosing, drug exposure (pharmacokinetics), and corresponding CNS functional effects (pharmacodynamics) to enhance the safety and efficacy of pediatric clinical trials. The overarching objective is to develop pediatric-specific pharmacodynamic measures and integrate these with pharmacokinetic data to build reliable models that support psychiatric medication evaluations in young populations. Currently, applications are not being accepted; the notice serves to inform potential researchers to prepare collaborations and projects responsive to this goal. Experts in pediatric psychiatry, neuroimaging, pediatric clinical pharmacology, and clinical trials are encouraged to consider future participation. For more information or inquiries, Margaret C. Grabb, Ph.D., is the provided contact.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Mental Health (NIMH) seeks research that helps determine the best dosing strategies when testing new psychiatric medications in children and adolescents with serious mental illnesses.This NOFO will focus on developing and refining central nervous system (CNS) tools and models that can show how medications affect the brain in young people. These tools might include functional brain imaging methods like EEG or fMRI, as well as digital health measures or cognitive assessments. Studies are encouraged that explore how dosing impacts drug exposure (pharmacokinetics) and related CNS functional effects (pharmacodynamics). The overall goal is to improve the safety and effectiveness of pediatric clinical trials by developing pediatric pharmacodynamic measures, to associate pharmacodynamic data with pharmacokinetic data, and to establish associated models. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Researchers with expertise in pediatric psychiatry, neuroimaging, pediatric clinical pharmacology, clinical trials, or related fields are encouraged to consider applying to the new NOFO.
